Insmed Inc.

Insmed Reports Financial Results for Second Quarter and First Half of 2007

Published in Healthcare Finance, Tax and Law Weekly, August 15th, 2007

Insmed Inc. (Nasdaq:INSM), (referred to herein as "Insmed", "we", "our" and "us"), a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs, announced results for the second quarter and six-month period ended June 30, 2007.

Revenues for the three months ended June 30, 2007 were $2.3 million, up from $210,000 from the corresponding period in 2006. The increase was due to two factors: improvements in cost recovery from Insmed's Expanded Access Program (EAP) to treat patients with amyotrophic lateral sclerosis (ALS) and the receipt of licensing income...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry